Châtillon, France, April 11, 2025 DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 ...

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company ...

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of ...

Shares of DBV Technologies (DBVT) are moving lower after the company a “substantial doubt regarding its ability to continue as a going concern.” When reporting unaudited results for 2024 ...

It’s been more than three years since DBV Technologies’ peanuty allergy therapy was rejected for FDA approval, but the company thinks it now has a clear route to market with its patch product ...

American depositary receipts of DBV Technologies gained after the company reported new financing of up to $306.9 million. The biopharmaceutical company's ADRs were up 57%, at $6.14, Friday morning.

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other ...

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a ...